Who
Bahija Jallal
Director
Company insider
Files Form 4 as: Director, Elevance Health; Chief Executive Officer, Immunocore Holdings; Director, ArriVent BioPharma; Director, Guardant Health.
In numbers
- Trades disclosed
- 33
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $742K
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 1 Feb 2018
- Last trade
- 13 May 2026
- Last filed
- 15 May 2026
Companies traded
Activity over time
1 Feb – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 May 2026filed 15 May 2026 | ELV Elevance HealthManaged Care & Insurers | SEC FORM 4 Code A | —563 at $0.00 | filing |
| 13 May 2026filed 15 May 2026 | ELV Elevance HealthManaged Care & Insurers | SEC FORM 4 Code A | —563 at $0.00 | filing |
| 18 Feb 2026filed 19 Feb 2026 | IMCR Immunocore HoldingsBiotechnology | SEC FORM 4 Sold | $371K11,474 at $32.35 | filing |
| 18 Feb 2026filed 19 Feb 2026 | IMCR Immunocore HoldingsBiotechnology | SEC FORM 4 Sold | $371K11,474 at $32.35 | filing |
| 17 Feb 2026filed 19 Feb 2026 | IMCR Immunocore HoldingsBiotechnology | SEC FORM 4 Code M | —23,817 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | IMCR Immunocore Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code M | —23,817 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | IMCR Immunocore Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code M | —23,817 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | IMCR Immunocore Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —88,573 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | IMCR Immunocore Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —395,066 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | IMCR Immunocore Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —88,573 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | IMCR Immunocore Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —395,066 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | IMCR Immunocore HoldingsBiotechnology | SEC FORM 4 Code M | —23,817 at $0.00 | filing |
| 14 May 2025filed 16 May 2025 | ELV Elevance HealthManaged Care & Insurers | SEC FORM 4 Code A | —601 at $0.00 | filing |
| 17 Feb 2025filed 19 Feb 2025 | IMCR Immunocore Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —405,824 at $0.00 | filing |
| 17 Feb 2025filed 19 Feb 2025 | IMCR Immunocore Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,270 at $0.00 | filing |
| 15 May 2024filed 17 May 2024 | ELV Elevance HealthManaged Care & Insurers | SEC FORM 4 Code A | —388 at $0.00 | filing |
| 16 Feb 2024filed 21 Feb 2024 | IMCR Immunocore Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —281,819 at $0.00 | filing |
| 25 Jan 2024filed 29 Jan 2024 | AVBP ArriVent BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,884 at $0.00 | filing |
| 10 May 2023filed 12 May 2023 | ELV Elevance HealthManaged Care & Insurers | SEC FORM 4 Code A | —457 at $0.00 | filing |
| 15 Jun 2022filed 17 Jun 2022 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —1,814 at $0.00 | filing |
News
Immunocore (NASDAQ:IMCR) Shares Up 8% – Here's WhyIMCR · dailypolitical.com · 20 Oct 2026
0 headlines in the last 90 days name Bahija Jallal; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.